Researchers at the University of Oxford (UK) are racing against time to get the Covid-19 vaccine on a large-scale production line from September.
According to Bloomberg, the research team of Professor Sarah Gilbert of Oxford University has mobilized more than 500 volunteers aged 18-55 in the Covid-19 vaccine testing program. This program will be extended to older people and reach a maximum of 5,000 people in the final stages.
“We expect to have at least a few doses of the vaccine to hit the market by September. By then, there won’t be enough vaccines for all, but now the more we produce, the more vaccine to use at the time, “Professor Gilbert said.
Professor Gilbert has been studying vaccines at Oxford University since 1994. In March, the National Institutes of Health and the British Institute for Innovation and Research provided £ 2.2 million (US $ 2.8 million) for her team to support research on the Covid-19 vaccine.
Professor Gilbert’s group is one of the first organizations in the world to test a vaccine against Covid-19. The World Health Organization (WHO) says there are 70 types of vaccines being developed and three vaccines are being tested in humans.
The three vaccines come from CanSino Biological and the Beijing Biotechnology Institute, Inovio Pharmaceutical Company, Moderna and the National Institute of Allergy and Infectious Diseases.
Gilbert’s test divided 510 volunteers into 5 groups and followed up for 6 months. One of them will receive a second injection 4 weeks after the initial injection.
Research the vaccine (called ChAdOx1 nCoV-19) to determine the effectiveness, safety and immunity of this vaccine. The vaccine works by helping the immune system identify and attack corona virus, stimulating T-cell responses.
Gilbert’s team uses the technology used to develop the MERS vaccine. However, the problem with determining the effectiveness of the vaccine is that the disease activity in the regions is not the same.
“The test must be used at the right place at the right time, it is difficult to predict that. That’s why we plan to conduct testing in many countries,” Ms. Gilbert said.
Another obstacle is the capital. “We have the money but we can’t cover it all. You cannot start large-scale right away. This project can cost tens of millions of dollars,” she added.
According to Gilbert, WHO has created a forum for all vaccine developers Covid-19 to share the plan and initial findings. “The work is progressing at a very fast pace. I am sure that we will see an unprecedented spirit of cooperation towards a global goal of preventing Covid-19 through vaccination,” she said. emphasize.